Delta Development Team Selected for $1.57M TACFI Opportunity to Advance Total Blood System (TBS)

Tucson, Arizona – April 17, 2025 – Delta Development Team (DDT) is proud to announce that it has been selected for a $1.57 million Tactical Funding Increase (TACFI) opportunity by AFWERX, the innovation arm of the Department of the Air Force and a directorate within the Air Force Research Laboratory.  The phase IIB award represents a partnership between DDT, AFWERX, the 59th Medical Wing’s Office of the Chief Scientist, the Center for Sustainment of Trauma and Readiness Skills (C-STARS), and Air Mobility Command. This funding will accelerate the development of DDT’s groundbreaking Total Blood System (TBS), a revolutionary technology poised to transform blood management for enroute military care, battlefield distribution, and prehospital blood transfusion programs for emergency healthcare.Continue reading

Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

    • Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes.
    • Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes.
    • For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system.

Continue reading

New 3D technology paves way for next-generation eye tracking

Eye tracking plays a critical role in the latest virtual and augmented reality headsets and is an important technology in the entertainment industry, scientific research, medical and behavioral sciences, automotive driving assistance and industrial engineering. Tracking the movements of the human eye with high accuracy, however, is a daunting challenge.Continue reading

Picard Medical Plans IPO on the NYSE

Picard Medical, Inc. is a holding company that owns 100% of the membership interests of SynCardia Systems, LLC (“SynCardia”).  A medical technology company based in Tucson, AZ, SynCardia manufactures and sells the only U.S. Food and Drug Administration (“FDA”), and Health Canada approved implantable total artificial heart (the “SynCardia TAH”). To date, over 2,100 SynCardia TAHs have been implanted in patients in 27 countries and the SynCardia TAH is an established bridge to heart transplantation for patients with biventricular failure in the U.S., and around the world.

Continue reading

BIRD Foundation Call for Proposals – May 14 2025 Deadline

The BIRD Foundation was established by the U.S. and Israeli governments in 1977 to generate mutually beneficial cooperation between U.S. and Israeli companies, including start-ups and established organizations. BIRD provides both matchmaking support between U.S. and Israeli companies, as well as funding covering up to 50 percent of project development costs, up to $1.5M per project. BIRD takes no equity in the companies.Continue reading